Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

SEC Filing · 20-F/A

Anbio Biotechnology

NNNNNASDAQEQUITYCurrent

SEC Filing

Filed Apr 9, 2026Accepted Apr 9, 2026, 6:04 AM EDTCIK 1982708Accession 0001185185-26-001313
Share

Company context

Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions. By doing so, we aim to significantly enhance patient prognosis and contribute to the betterment of healthcare worldwide. At Anbio Biotechnology, our extensive portfolio comprises an array of IVD products designed to cater to diverse diagnostic needs. Our comprehensive range encompasses solutions for various applications, including over-the-counter (OTC) utilization, point-of-care (POCT) settings, and laboratory applications. By offering a versatile range of products, we ensure that healthcare providers and patients alike can access reliable and efficient diagnostic tools regardless of the healthcare setting.

Current securities

Recent company filings

  1. F-3ASR filingJul 9, 2026
  2. 6-K filingMay 19, 2026
  3. 6-K filingApr 27, 2026
  4. 20-F filingApr 7, 2026
  5. 6-K filingFeb 17, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗